Bone Biologics Corp Warrants

Bone Biologics Corporation announced a private placement of 2.1 million shares at $1.42 per share, raising $3.0 million upfront with potential additional $6.0 million from warrant exercises. The company plans to use proceeds for clinical trials, patent portfolio maintenance, and working capital. Closing expected July 9, 2026.

Bone Biologics announced 2025 achievements including extending rhNELL-1 shelf life to 24 months, completing a $5 million public offering, filing new patent applications, and maintaining Nasdaq compliance. The company plans to continue advancing its NB1 clinical trial in 2026 with focus on patient enrollment completion and operational readiness.